论文部分内容阅读
原发性肝癌早期诊断是改善预后的关键。AFP 联合肝脏超声筛查和随访是早期诊断的主要途径,但对慢性肝病基础上较为常见的良性病变与小肝癌的鉴别仍较困难。AFP≥200μg/L 作为诊断肝癌临界值(cut-off 值),敏感度仅为20%～45%。AFP 异质体(AFP-L3)检测等对肝癌有很好的特异度,但是敏感度也低。磷脂酰肌醇硫酸类肝素蛋白聚糖3(glypican-3,GPC3)是通过磷脂酰肌醇(GPI)锚定于细胞膜表面脂质的硫酸类肝素蛋白聚糖,参与调节胚胎生长发育。国外研究显示,GPC3在80%～90%肝癌组织中表达水平显著上调,在正常成人组织和其他肿瘤中低水平表达或不表达,约50%肝癌患者血清中亦可检测到升高水平的可溶性 GPC3蛋白,可能是一个值得期待的肝癌特异性标志。本研究采用 ELISA 测定肝癌和肝硬化患者血清
Early diagnosis of primary liver cancer is the key to improving prognosis. AFP combined with liver ultrasound screening and follow-up is the main method of early diagnosis, but the more common on the basis of chronic liver disease, benign lesions and the identification of small liver cancer is still more difficult. AFP≥200μg / L as a cut-off value for the diagnosis of liver cancer, the sensitivity was only 20% to 45%. AFP heterogeneity (AFP-L3) detection of liver cancer has a very good specificity, but the sensitivity is also low. Phosphatidylinositol glyceryl glycoside 3 (glypican-3, GPC3) is a heparan sulfate proteoglycan that is anchored on the surface lipid of cell membranes by phosphatidylinositol (GPI) and is involved in the regulation of embryonic growth and development. Foreign studies have shown that GPC3 expression was significantly upregulated in 80% -90% of HCC tissues, with low or no expression in normal adult tissues and other tumors, and elevated levels were also detectable in the serum of approximately 50% of HCC patients GPC3 protein may be a worthwhile look for liver cancer-specific markers. In this study, serum of patients with liver cancer and cirrhosis was detected by ELISA